Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study investigates whether mirabegron (YM178) has an effect on the pharmacokinetics of solifenacin and whether solifenacin has an effect on the pharmacokinetics of mirabegron.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male subject must agree to sexual abstinence and/or use a highly effective method of birth control from screening until 3 months after last dose of study medication
Female subject must be of non-child bearing potential, i.e. post menopausal, surgically sterilized (e.g. tubal ligation), hysterectomy in medical history, or must practice an adequate non-hormonal contraceptive method to prevent pregnancies. Non-hormonal contraceptive methods are defined as:
Body Mass Index between 18.5 and 30.0 kg/m2, inclusive
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
41 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal